Hepatitis C
Conditions
Brief summary
Patients who completed the conventional treatment against HCV and relapsed (the virus appeared again in their blood) have no effective therapy.
Detailed description
The rational behind the proposed study is that most patients can not tolerate the prolonged IFN injections because the side effects. The new proposed treatments allows continous low doses of IFN to be secreted by the patients himself using his own skin in which the dermo fibroblasts are enriched by a human gene of erythropoietin. The biopump continues to secret the IFN for several months avoiding the spikes of IFN in the plasma which are beleived to cause the undesired effects. Patients will be able to complete a long treatment with low IFN dose and Ribavirin hoping to induce prolonged remission and cure
Interventions
Subcutan implantation of autologus skin graft after ex-vivo treatment
Sponsors
Medgenics Medical Israel Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Signed patient consent form * Chronic HCV patients in relapse following conventional treatment regimen (INF+Ribavirine) with detectable plasma level of HCV RNA * Hepatitis B and human immunodeficiency virus negative at screening visit * Able and willing to follow contraception requirements * Screening laboratory values, test, and physical exam within acceptable range
Exclusion criteria
* Current enrollment in another investigational device or drug study * Anticipated inability to complete all clinic visits and comply with study procedures * History of, or any current medical condition, which could impact the safety of the subject during the study * Autoimmune hepatitis, suspected hepatocellular carcinoma, decompensated liver disease, or other known liver disease other than HCV * Alcoholism or substance abuse with \<6 documented months of sobriety * Known allergy or sensitivity to interferons or ribavirin * Any other condition that, in the opinion of the Investigator, would make the subject unsuitable for enrollment or could interfere with the subject participating in and completing the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and Efficacy of Sustained Interferon Alfa 2b (INF) Therapy of Relapsing Hepatitis C (HCV) Patients using InfraDure Biopump | 9 months | All subjects will receive autologous InfraDure Biopump tissue implants intended to provide sustained production and delivery of therapeutic levels of INF for up to three (3) months following INFRADURE Biopump implantation, with possibility of extension for an additional six months for a total of 9 month post INFRADURE Biopump implantation. Saftey parameters (Adverse events and Serious Adverse Events as well as immediate and long term tolerability are the main safety parameters |
Countries
Israel
Outcome results
None listed